SCHEMBL16455152

SCHEMBL16455152

CN1CCN(C(=O)[C@H](CCCC=O)NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 20/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22856663 1.00 KDM1A (0.58) KDM1A
SCHEMBL19628624 0.93 KDM1A (0.56) KDM1A
SCHEMBL16448261 0.89 KDM1A (0.52) KDM1A
SCHEMBL16448263 0.89 KDM1A (0.52) KDM1A
SCHEMBL16455064 0.87 KDM1A (0.60) KDM1A
SCHEMBL16455151 0.86 KDM1A (0.59) KDM1A
SCHEMBL22856674 0.86 KDM1A (0.59) KDM1A
SCHEMBL26148130 0.86 KDM1A (0.59) KDM1A
SCHEMBL17984258 0.86 KDM1A (0.60) KDM1A
SCHEMBL18848746 0.85 KDM1A (0.58) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-20210147373-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-05-20 US disclosed
US-10370346-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2019-08-06 US disclosed
US-20170334873-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2017-11-23 US disclosed
US-20170334873-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2017-11-23 US disclosed
US-9790195-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2017-10-17 US disclosed
US-9790195-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2017-10-17 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
WO-2015021128-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC. (US) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334873-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885
US-10370346-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885
US-20210147373-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885
US-11655226-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.